Literature DB >> 6163722

Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged.

R Berger, G Florent, M Just.   

Abstract

Humoral antibodies and specific cellular immune reactions (proliferative immune response in the lymphocyte transformation test) to varicella-zoster virus antigen were measured in children, young adults, and elderly people. In children and young adults, the humoral varicella-zoster-specific antibodies and the virus-specific cellular immune response generally coincided. In the over-60 age group, however, a discrepancy was often observed between these parameters. Ninety percent of the elderly subjects showed humoral antibodies, but only 64% still had a measurable varicella-zoster-specific immune response. There was no correlation between the magnitude of the virus antigen-specific immune response and the mitogen-induced lymphoproliferative response (phytohemagglutinin stimulation). One in three elderly people, therefore, showed no cellular immune response to the varicella-zoster virus antigen, and this person could probably be regarded as a potential herpes zoster patient.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6163722      PMCID: PMC350580          DOI: 10.1128/iai.32.1.24-27.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Cell-mediated immunity to varicella zoster virus in children being treated for cancer.

Authors:  F A Hayes; S Feldman
Journal:  Cancer       Date:  1978-07       Impact factor: 6.860

2.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Zoster, reinfection or activation of latent virus? Observations on the antibody response.

Authors:  L H Miller; P A Brunell
Journal:  Am J Med       Date:  1970-10       Impact factor: 4.965

4.  A rapid microtechnique for in vitro stimulation of human lymphocytes by phytohemagglutinin.

Authors:  M A Pellegrino; S Ferrone; A Pellegrino; R A Reisfeld
Journal:  Clin Immunol Immunopathol       Date:  1973-11

5.  Cellular immunity in host resistance to viral infections.

Authors:  L A Glasgow
Journal:  Arch Intern Med       Date:  1970-07

6.  Increased proliferative response of human peripheral blood lymphocytes to anti-immunoglobulin antibodies in elderly people.

Authors:  H L Weiner; D J Scribner; A L Schocket; J W Moorhead
Journal:  Clin Immunol Immunopathol       Date:  1978-03

7.  Cell-associated immunity to measles (rubeola). The demonstration of in vitro lymphocyte tritiated thymidine incorporation in response to measels complement fixation antigen.

Authors:  K D Graziano; J C Ruckdeschel; M R Mardiney
Journal:  Cell Immunol       Date:  1975-02       Impact factor: 4.868

Review 8.  Immunobiology of aging: evaluation of current status.

Authors:  M M Kay; T Makinodan
Journal:  Clin Immunol Immunopathol       Date:  1976-11

9.  The demonstration of cell-associated immunity to viruses. In vitro lymphocyte responsiveness to Varicella-zoster antigen.

Authors:  J C Ruckdeschel; M R Mardiney
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

10.  Abnormalities of cellular immune response in arthritis induced by rubella vaccination.

Authors:  Y Chiba; E Sadeghi; P L Ogra
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

View more
  39 in total

1.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

2.  Vaccination to prevent zoster in the elderly.

Authors:  A A Gershon
Journal:  Epidemiol Infect       Date:  2007-08       Impact factor: 2.451

3.  Can herpes zoster be prevented?

Authors:  M J Levin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

Review 4.  Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey.

Authors:  Mohamed A ElTanbouly; Randolph J Noelle
Journal:  Nat Rev Immunol       Date:  2020-10-19       Impact factor: 53.106

Review 5.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Lymphocyte responses to varicella zoster virus in the elderly.

Authors:  A R Hayward; M Herberger
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

7.  Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Jesse Dewane; Joshua Walker; Wayne Gray; Ilhem Messaoudi
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

8.  Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs.

Authors:  A R Hayward; R Burger; R Scheper; A M Arvin
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Authors:  Adriana Weinberg; Jane H Zhang; Michael N Oxman; Gary R Johnson; Anthony R Hayward; Michael J Caulfield; Michael R Irwin; James Clair; Jeffrey G Smith; Harold Stanley; Rocio D Marchese; Ruth Harbecke; Heather M Williams; Ivan S F Chan; Robert D Arbeit; Anne A Gershon; Florian Schödel; Vicki A Morrison; Carol A Kauffman; Steve E Straus; Kenneth E Schmader; Larry E Davis; Myron J Levin
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

10.  Concurrent reactivation of varicella zoster virus and herpes simplex virus in an immunocompetent child.

Authors:  Hyun-Ho Park; Mu-Hyoung Lee
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.